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Endothelial cellsen reported concerning the role of AMP-activated protein kinase (AMPK) in
mediating thrombin stimulation of endothelial NO-synthase (eNOS). We examined the involvement of two
upstream kinases in AMPK activation in cultured human umbilical endothelial cells, LKB1 stimulated by a
rise in intracellular AMP/ATP ratio, and Ca+2/CaM kinase kinase (CaMKK) responding to elevation of
intracellular Ca+2. We also studied the effects of AMPK activation on the downstream target eNOS. In culture
medium 1640 the level of intracellular ATP was unchanged after thrombin stimulation and the CaMKK
inhibitor STO-609 totally inhibited phosphorylation of AMPK and acetyl coenzyme A carboxylase (ACC) but
not eNOS. In Morgan's medium 199 thrombin caused a signiﬁcant lowering of intracellular ATP and STO-609
only partially inhibited the phosphorylation of AMPK, ACC and eNOS. Inhibition of AMPK by Compound C or
AMPK downregulation using siRNA partially inhibited the phosphorylation of eNOS in medium 199 but not
in 1640, underscoring a clear difference in the pathways mediating thrombin-stimulated eNOS
phosphorylation in different culture media. Thus, conditions subjecting endothelial cells to a fall in ATP
after thrombin stimulation facilitate activation of pathways partly dependent on AMPK causing downstream
phosphorylation of eNOS. In contrast, under culture conditions that do not facilitate a fall in ATP after
stimulation, AMPK activation is exclusively mediated by CaMKK and does not contribute to the
phosphorylation of eNOS.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionThe vascular endothelium regulates vascular tone by releasing
numerous vasodilators and vasoconstrictors. The most important
vasodilator is nitric oxide (NO) produced from arginine by endothelial
nitric oxide synthase (eNOS). Besides causing vasodilation, NO inhibits
platelet aggregation, leukocyte adherence and smooth muscle cell
proliferation. These effects exert a profound inﬂuence on blood ﬂow,
vascular remodeling and angiogenesis. Loss of endothelial function
due to either decreased production or increased degradation of NO is
associated with several cardiovascular disorders, including athero-
sclerosis [1].; AICAR, 5-aminoimidazole-4-
d protein kinase; CaMKK, Ca+2/
UVEC, human umbilical vein
oxide
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son).
l rights reserved.eNOS activity is regulated by numerous stimuli, including shear
stress, growth factors, vasoactive compounds and hypoxia. The
activity is inﬂuenced by the subcellular location of the enzyme and
the formation of complexes with regulatory proteins, by Ca+2 levels
and phosphorylation at several sites by a variety of protein kinases [2].
Phosphorylation at Ser1177 has been most thoroughly studied and
appears to enhance the sensitivity of eNOS to Ca+2 thus promoting its
activation. Recently, phosphorylation at this site was shown to
modulate vascular reactivity and outcome of cerebral ischemia in
vivo [3]. Several protein kinases have been implicated in the
phosphorylation at Ser1177 [4].
AMP-activated protein kinase (AMPK) is an energy sensor often
referred to as a cellular metabolic master switch. It is activated by any
stress causing an increase in the AMP/ATP ratio [5,6]. Once activated,
AMPKmaintains intracellular energy balance by turning down energy
consuming pathways and switching on ATP generating pathways.
AMPK also plays a role in whole body energy balance and food intake
[6]. Activation of AMPK requires phosphorylation at threonine 172 of
the catalytic α subunit caused by an upstream AMPK kinase. A known
tumor suppressor, LKB1 phosphorylates this site in response to
lowered ATP/AMP ratio. By this phosphorylation mediated by LKB1,
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within the cell, thereby inhibiting ATP consumption and increasing
ATP production.
Recently, it has been shown that activation of AMPK is not
exclusively associated with perturbations in the ATP/AMP ratio. The
Ca+2/calmodulin dependent kinase kinase β (CaMKKβ) has been
shown to phoshorylate and activate AMPK in response to elevation
of intracellular Ca+2 [7–11]. Among the mammalian kinases CaMKK is
the closest relative to the AMPKK orthologues in Saccharomyces
cerevisiae [10]. da Silva et al. [12] identiﬁed CaMKK as the kinase
involved in extracellular nucleotide mediated AMPK activation in
endothelial cells. Furthermore, theydemonstrated that the nucleotides
activated AMPK in HeLa cells known to be deﬁcient in LKB1.
We have previously reported that the G-protein activators thrombin
and histamine stimulate NO-production and phosphorylation of eNOS
at Ser1177 in human umbilical vein endothelial cells (HUVEC) in a Ca+2-
dependent but PI3 K/Akt independent manner and provided evidence
that AMPK is involved in mediating the stimulation [13]. In contrast to
our ﬁndings, Stahmann et al. [14] did not ﬁnd a role for AMPK in
mediating thrombin-stimulated eNOS phosphorylation. They identiﬁed
CaMKKβ as the sole upstream kinase responsible for AMPK phosphor-
ylation since downregulation of LKB1 did not affect thrombin-induced
AMPK activation and there was no signiﬁcant change in the AMP/ATP
ratio upon thrombin stimulation. Inhibition of either CaMKKβ or AMPK
by pharmacological inhibition or protein downregulation using RNA
interference, showed that thrombin-induced eNOS phosphorylation
was not mediated by the CaMKKβ/AMPK pathway. Motley et al.
obtained similar results and further demonstrated by the use of
adenovirus encoding dominant-negative mutants of protein kinase C
δ (PKCδ) and PKC inhibitors the involvement of PKCδ in eNOS
phosphorylation after thrombin treatment [15]. There are important
methodological differences between these two and our previous
studies. The aim of the present study therefore was to explore these
discrepancies on the mechanism of thrombin mediated eNOS phos-
phorylation, besides further clarifying the involvement of upstream
kinases. The results presented here demonstrate that two pathways are
involved in activating AMPK after treatment with thrombin, phosphor-
ylation stimulated by lowering of the ATP/AMP ratio and CaMKK
dependent activation. Only when stimulated by a fall in ATP/AMP ratio
does AMPK mediate stimulation of eNOS. When the experimental
conditions do not allow or facilitate a fall in ATP after thrombin
stimulation the upstream activation of AMPK is exclusively through
CaMKK and while stimulating the phosphorylation of acetyl-CoA
carboxylase (ACC) it does not affect eNOSphosphorylation or activation.
2. Materials and methods
2.1. Materials
EBM-2 was purchased from Clonetics. Other cell culture media,
Foetal Bovine Serum and Penicillin-Streptomycin were purchased
from Gibco Brl, Life Technologies. Tissue culture plates (35 mm)
and ﬂasks (50 mL) were from Nunc, Cryotin×(trypsin) from cod
was provided by The Science Institute of Iceland. Thrombin,
A23187, L-NA, Trypsin-EDTA Solution, Direct cGMP enzyme immu-
noassay kit, isobutylmethylxanthine (IBMX), apyrase and acid phos-
phatase were purchased from Sigma. STO-609 and Compound C were
from Calbiochem. Hybond ECL Nitrocellulose membrane (6×8 cm),
ECL+PLUSWestern blotting detection system and Hyperﬁlm ECL High
performance chemiluminescence ﬁlm were from Amersham Pharma-
cia Bioteck. Antibodies against eNOS, phospho-eNOS (Ser1177), AMPK,
phospho-AMPK (Thr172), AMPKα1, AMPKα2, Pan-Actin and Anti-
Rabbit IgG/HRP-linked came from Cell Signaling Technology. Anti-
bodies against ACC and phospho-ACC (Ser79) were from Upstate.
Lipofectamine™ RNAiMAX Reagent was from Invitrogen. AMPKα1 and
AMPKα2 siRNA came from Ambion.2.2. Cell culture
Endothelial cells were cultured from human umbilical veins by a
modiﬁcation of the method of Jaffe et al. as previously reported [16].
The cells were harvested by Cryotin X trypsin digestion and seeded on
35 mm culture dishes in Morgan's medium 199 containing 20% foetal
bovine serum and antibiotics (penicillin, 100 U/mL and streptomycin,
100 μg/mL). The culture dishes were incubated at 37 °C in humidiﬁed
air with 5% CO2. The mediumwas changed 24 h after seeding the cells
and then every 2–3 days thereafter until the cell culture reached
conﬂuence (after ∼7 days).
When conﬂuent the cells were washed with the appropriate
medium and placed in 1.0 mL medium with or without inhibitors at
the indicated concentrations. Agonist was added 10 to 20 min later in
a concentration calculated to reach the intended concentration for
each experiment and left on for additional 2 to 20 min. The agonists
were then removed along with the medium and cellular reactions
terminated by adding 250 μL SDS sample buffer. The samples were
boiled for 5 min and centrifuged for 10 min at 3000 rpm. The samples
were then ready to be either used or stored at −20 °C.
HeLa cells were cultured in medium 199 containing 10% fetal
bovine serum and antibiotics (penicillin, 100 U/mL and streptomycin,
100 μg/mL).
2.3. siRNA transfection
Endothelial cells grown to ca 80% conﬂuence in 50 mL tissue
culture ﬂasks were trypsinized and deluted sixfold on to 35 mm
culture dishes. 24 h later, the cells were transfected with Lipofecta-
mine™ RNAiMAX transfecting agent containing siRNA for AMPKα1
and/or AMPKα2 (20 nM) in antibiotics-free EBM-2 medium contain-
ing 6% serum. Cells were cultured for 44 h and protein expression
analyzed by Western blotting.
2.4. Electrophoresis and immunoblotting
Samples (8 μL) were resolved by SDS-PAGE (10%). The gels were
blotted and the proteins thereby transferred to nitrocellulose. The
membranes were hybridized with the indicated antibodies and
subsequently with a secondary antibody (Anti-Rabbit IgG/HRP-
linked). The immuno-complexes were detected with ECL+PLUS
Western blotting detection system and developed onto a ﬁlm. Equal
loading was ascertained by hybridizing membranes with antibodies
against unphosphorylated protein. The band intensity was quantiﬁed
using Kodak 3.5 software.
2.5. Measurement of ATP
ATP was determined by luciferase assay and for validation by HPLC
in which case AMP was also determined. For ATP determination using
the luciferase assay the medium was removed from the cells and the
cells lyzed by adding 0.5 mL of 0.5 N perchloric acid. After 30 min a
10 μL sample was diluted×100 in water mixed with 80 μL of a
luciferase mixture from an Eliten kit by Promega. For HPLC analysis,
the cells were killed by adding 0.25 mL of 0.5 M perchloric acid. The
cells were scraped off the culture dishes, put into Eppendorf tubes,
neutralized with 220 μL of 5 N KOH and centrifuged at 10,000 g for
10 min. 225 μL of the supernatant was transferred to another tube
containing 25 μL of 1 M KH2PO4 pH 6.0. The nucleotides were
determined by reversed phase HPLC in an Agilent 1100 apparatus
using a 15 cm Zorbax C8 column and a mobile phase which was a
variablemixture of 100mMKH2PO4 pH 6.0 and 8mMTMA counterion
and the same solution containing 10% methanol. According to this
method the level of cellular AMP was 3% of the ATP levels and when
cells were stimulated with the Ca+2 ionophore A23187 the AMP levels
doubled for every 22% lowering of ATP (not shown).
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HUVEC monolayers were washed with Morgan's medium 199 or
medium1640 and placed in 1.0 mL Morgan's medium 199 or medium
1640 containing 0.25 mM IBMX. The cells were incubated for 17 min.
at 37 °C. Then thrombinwas added to give a ﬁnal concentration of 1 U/
mL and the cells further incubated for 3min. The reactionwas stopped
by removing themedium and adding 0.5mL of 0.1MHCL. Intracellular
cGMP was determined using an enzyme immunoassay kit (Sigma) in
accordance with the manufacturer's instructions.
2.7. Statistical analysis
Values are expressed as average±S.D. Unpaired, two-tailed
Student's t-test was performed for comparisons between groups.
The level of signiﬁcance was set at pb0.05. Software used was
GraphPad Prism 5.00.Fig. 1. Effects of thrombin or A23187 on ATP levels in different media. (A) Comparison betwe
levels of cells in media 199, 1640 or buffer. Effect of 2–60 min pre-treatment of medium 199
with A23187. (†ns vs. unstimulated cells; #pb0.001 vs. unstimulated cells, ⁎pb0.001 vs. cells
media on ATP levels of HUVEC after treatment with the Ca+2 ionophore A23187. The cells wer
media. After 20min the cells were treatedwith 0.6 μMA23187 for 3min and ATP levels determ
The cells were cultured inmedium 199. 20min before treatment, themediumwas replaced ei
for the indicated times, boiled for 2 min and cooled to 37 °C. Results are expressed as percen
three independent experiments each done in duplicate. TPP, tocopheryl phosphate.3. Results
3.1. Effects of thrombin or A23187 on cellular ATP content in different
media
To investigate the upstream mechanisms of AMPK activation in
endothelial cells the levels of cellular ATP were measured following
treatment with thrombin or the Ca+2 ionophore A23187 in different
media. As the Ca+2 ionophore was more potent in lowering the ATP
level it was used in further studies of intracellular ATP. In medium
199, treatment with 1 U/mL of thrombin for 3 min lowered
intracellular ATP by 10.7±4.1%, whereas in medium 1640 the effect
of thrombin was negligible (lowering of 2.0±2.6%) (Fig. 1A).
Treatment with A23187 at 0.6 μM revealed a marked difference
between responses in the two media, a 53.3±2.5% lowering of ATP in
medium 199 compared to no decrease in medium 1640 (2.0±4.0%)
(Fig. 1A). Fig. 1A also shows that treatment with A23187 in buffer haden the effects of 3 min treatment with thrombin (1 U/mL) and A23187 (0.6 μM) on ATP
with apyrase (1 U/mL) on the decrease in cellular ATP levels caused by 3 min treatment
stimulated with A23187 in medium 199 not treated with apyrase). (B) Effects of culture
e cultured in normal medium 199 and subsequently transferred to the various indicated
ined. (†ns vs control; ⁎pb0.05 vs. cells treated with A23187 alone; #pb0.01 vs. control).
ther with freshmedia 1640 or 199 ormedium 199 treatedwith apyrase (1 U/mL) at 37 °C
t ATP level relative to control (unstimulated cells) and show the average±S.D. of at least
Fig. 2. The effects of CaMKK inhibition on thrombin mediated phosphorylation of
AMPK, ACC and eNOS inmedium 199. The effects of 20min pre-treatment with STO-609
(10 μM) on (A) AMPK (Thr172), (B) ACC (Ser79) and (C) eNOS (Ser1177) phosphorylation
caused by thrombin (1 U/mL, 2 min) in medium 199. Conﬂuent endothelial cells were
stimulated as indicated, lysates were electrophorized and blotted as described in
Materials and methods and detected using antibodies against AMPK, Thr172
phosphorylated AMPK, eNOS, Ser1177 phosphorylated eNOS, ACC and Ser79 phos-
phorylated ACC. The results are expressed as percent phosphorylation relative to
unstimulated cells and show the average±S.D. of three independent experiments.
(⁎pb0.05 cells treated with STO-609 and thrombin vs. cells stimulated with thrombin
alone).
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allowed or facilitated the drop in ATP levels in response to both
thrombin and Ca+2 ionophore A23187.
A potentially important difference in the composition of the two
media is the presence of ATP and other purines in medium 199 and
their absence in 1640. As shown in Fig. 1A treatment of medium 199
with 1 U apyrase for 1 h followed by boiling and cooling to 37 °C before
adding the medium to cells markedly reduced the ionophore
mediated lowering of cellular ATP. However, adding ATP to medium
1640 or to medium 199 treated with apyrase did not restore the
lowering effect of A23187 on cellular ATP (data not shown).
Furthermore, the reduction of cellular ATP after A23187 treatment
was identical in medium 199 manufactured without purines, ribose
and deoxyribose to that in normal medium 199 (Fig. 1B) and the effect
was also reduced by apyrase pre-treatment.
As the commercially available apyrase contains acid phosphatase
we tested the effects of pure acid phosphatase on the cellular
responses to stimulation in medium 199. After 1 min treatment of
199 with phosphatase no detectable ATP was present in the medium
and pre-treating the cultured endothelial cells with phosphatase in
fresh medium 199 decreased the ionophore stimulated fall in cellular
ATP from 53±3% to 9±1% of control values. However, the phosphatase
also prevented the ATP fall in cells in medium 199 manufactured
without purines, ribose and deoxyribose. Taken together, these results
excluded the possibility that ATP in the medium or the products of
apyrase-mediated ATP hydrolyzation in medium 199 could be the
explanation for different cell responses in different media.
Another difference between the two media is the presence of
vitamins A, D, C and K, tocopheryl phosphate, cholesterol and the
non-ionic detergent tween 80 in medium 199 and their absence in
1640. In view of our results with phosphatase treatment the presence
of tocopheryl phosphate in medium 199 was potentially interesting.
However, the response in medium 199 manufactured without
tocopheryl phosphate was no different from that in ordinary medium
199 (Fig. 1B) and adding tocopheryl phosphate to medium 1640 had
no effect on ATP levels after A23187 treatment. Adding all the lipid
soluble vitamins or cholesterol to medium 1640 in various combina-
tions had no effect either (data not shown). However, as shown in
Fig. 1B, after adding tween 80 to medium 1640 subsequent treatment
with A23187 lowered intracellular ATP to 85.4±6.4% of control cells
(pb0.05). Similar effects of tween 80 were seen in Williams medium
which contains the same vitamins as medium 199 but no cholesterol
and no tween 80. In this medium the ionophore caused ATP
reduction to 82.5±8.4% of control and pre-treatment with tween
80 increased this effect to an ATP lowering of 50.0±12.0% of control
(Fig. 1B).
3.2. Thrombin mediated phosphorylation of AMPK, ACC and eNOS in
different culture media
The effects of the CaMKK inhibitor STO-609 on AMPK, ACC and
eNOS phosphorylation after treatment with thrombin are shown in
Fig. 2. When the experiments were carried out in culture medium 199
there was a sixfold increase in the phosphorylation of AMPK (Fig. 2A).
STO-609 partially inhibited this phosphorylation (72±11% reduction)
and also the thrombin mediated phosphorylation of ACC (66±4%
reduction) (Fig. 2B) and eNOS (54±14% reduction) (Fig. 2C).
When the cells were transferred to medium 1640 30 min before
thrombin treatment there was a fourfold activation of AMPK
phosphorylation (compared to sixfold increase in medium 199)
which was totally inhibited by STO-609 (94.8±6.4% reduction) (Fig.
3A), suggesting activation through CaMKKonly and no dependence on
another pathway. The phosphorylation of ACC was also completely
inhibited by STO-609 (104.5±12.8% reduction) (Fig. 3B) in contrast to
the eNOS phosphorylation which was unaffected (1.2±13.9% reduc-
tion) (Fig. 3C). However, when cellular ATP was lowered by pre-
Fig. 3. The effects of CaMKK inhibition on thrombinmediated phosphorylation of AMPK,
ACC and eNOS in medium 1640. The effects of 20 min pre-treatment with STO-609
(10 μM) on (A) AMPK (Thr172), (B) ACC (Ser79) and (C) eNOS (Ser1177) phosphorylation
caused by thrombin (1 U/mL, 2 min) in medium 1640. (D) Modiﬁcation of the effects of
STO-609 on thrombin mediated eNOS phosphorylation by 2-deoxy-glucose (20 mM,
4 min) in medium 1640. Cells were treated and results expressed as described in Fig. 2
and show the average±S.D. of three independent experiments. (†ns/⁎pb0.05 cells
treated with STO-609 and thrombin vs. cells treated with thrombin alone).
Fig. 4. Effects of STO-609 on AMPK phosphorylation in HeLa cells in medium 199. The
effects of 20 min pre-treatment with STO-609 (10 μM) on AMPK phosphorylation
(Thr172) in HeLa cells after treatment with A23187 (0.2 μM, 3 min) or histamine (10 μM,
3 min). Cells were treated and results expressed as described in Fig. 2 and show the
average±S.D. of four independent experiments. (⁎pb0.0001 cells treated with STO-609
and A23187 vs. cells treated with A23187 alone, ⁎⁎pb0.01 cells treated with STO-609
and histamine vs. cells treated with histamine alone) .
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ylation by 33.7±3.3% in medium 1640 (Fig. 3D).
To test the possibility that LKB1 is responsible for the STO-609
resistant activation of AMPK we used HeLa cells which are known to
be deﬁcient in LKB1 [17]. The HeLa cells were cultured and tested in
medium 199. STO-609 totally inhibited the phosphorylation of AMPK
caused by A23187 (98.0±4.9% inhibition) (Fig. 4A). Since HeLa cells do
not have a receptor for thrombin [18], we tested the effects of STO-609
on histaminemediated phosphorylation of AMPK and as seenwith the
Ca+2 ionophore, there was a total inhibition (100.9±2.5%) (Fig. 4B).
To test the possibility of eNOS being upstream of AMPK in the
activation cascade, we treated endothelial cells with thrombin after
20 min pre-treatment with the nitric oxide inhibitor N(G)-nitro-L-
arginine (L-NA). Although L-NA totally inhibited cGMP formation in
the cells, it had no effect on thrombin mediated phosphorylation of
AMPK, ACC or eNOS (data not shown).
3.3. The role of AMPK in eNOS phosphorylation and NO-production
To further investigate the possible involvement of AMPK in eNOS
phosphorylation in different media, we tested the effects of the AMPKinhibitor, compound C, on eNOS phosphorylation after treatment with
thrombin. As seen in Fig. 5A, compound C partially inhibited eNOS
phosphorylation in medium 199 while having no effect in medium
1640. In contrast, compound C inhibited the phosphorylation of ACC in
both media (Fig. 5B).
When acid phosphatase was added to medium 199, inhibition of
either CaMKK (STO-609) or AMPK (Compound C) had no effect on
eNOS phoshorylation, identical to the response in medium 1640 (Fig.
5C). Conversely, AMPK phosphorylation was totally inhibited by STO-
609 when phosphatase was added to medium 199, also identical to
that seen in medium 1640 (Fig. 5D).
Since the inhibitors used could possibly have off-target effects, we
used siRNA to suppress the expression of AMPKα. We transfected
validated siRNA constructs complementary to AMPKα1 and/or -α2
Fig. 5. AMPK inhibition in different media and the effects on thrombinmediated phosphorylation of ACC and eNOS. The effects of 20min pre-treatment with compound C (10mM) on
the phosphorylation of (A) eNOS (Ser1177) and (B) ACC (Ser79)mediated by thrombin (1 U/mL, 2min). Modiﬁcation by phosphatase (0.2mg/mL, 20min) of the effects of Compound C
or STO-609 (10 μM) on thrombin-induced phosphorylation of (C) eNOS and (D) AMPK (Thr172) in medium 199. (E) Total AMPK, AMPKα1 and AMPKα2 expression and thrombin-
stimulated phosphorylation of AMPK and eNOS after treatment of cells with siRNA for AMPKα1 (-α1) or AMPKα2 (-α2) or both simultaneously (-α1,α2) inmedium 199 or 1640. Cells
were treated and results expressed as described in Fig. 2 and show the average±S.D. of three independent experiments. (†ns/⁎pb0.05 cells treated with inhibitor and thrombin vs.
cells treated with thrombin alone; #ns/⁎⁎pb0.05 cells treated with thrombin and AMPK siRNA vs. cells treated with thrombin alone).
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analysis using isoform speciﬁc antibodies. The results are shown in
Fig. 5E. siRNA for AMPKα1 and -α2 suppressed the expression of
AMPKα1 and AMPKα2, respectively. siRNA downregulation of either
isoform had no effect on eNOS phosphorylation in media 199 or 1640.
However, simultaneous downregulation of both AMPKα1 and
AMPKα2 partially inhibited the phosphorylation of eNOS in medium
199 but had no effect in medium 1640.
The effect of AMPKα siRNA on NO-production was tested by
monitoring the accumulation of cGMP in cells after thrombinstimulation in different media. The results are shown in Fig. 6. In
agreement with the phosphorylation results, there was greater cGMP-
production in medium 199 than in medium 1640. Furthermore,
AMPKα siRNA reduced the cGMP-production after thrombin stimula-
tion only in medium 199.
In view of our results with tween 80 and ATP levels in medium
1640, we tested the effects of tween 80 on AMPK and eNOS
phosphorylation. As seen in Fig. 7A, adding tween 80 to medium
1640 changed the effects of STO-609 on thrombin mediated AMPK
phosphorylation towards the response seen in medium 199 (Fig. 2A).
Fig. 6. Thrombin-induced cGMP formation. Effect of simultaneous pre-treatment with
AMPKα1 and AMPKα2 siRNA in medium 199 and 1640. Endothelial cells were
stimulated by thrombin (1 U/mL, 2 min) with or without pre-treatment with AMPKα1
and -α2 siRNA. Intracellular cGMP was determined using an enzyme immunoassay kit
as described in Materials and methods. The results are expressed as percent of the
response in medium 199 without siRNA pre-treatment and show the average±S.D. of
four independent experiments each done in duplicate. (⁎pb0.05 vs. cells treated with
thrombin alone in medium 199).
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tion was partially inhibited by STO-609 and compound C (Fig. 7B) as
seen in medium 199 (Figs. 2C and 5A). The effects of these inhibitors
on eNOS phosphorylation also changed in Williams medium after the
addition of tween 80 (Fig. 7C). Similarly, when tween 80 was added to
Williams medium, AMPK phosphorylation was partially inhibited by
STO-609 in contrast to a total inhibition in Williams medium alone
(Fig. 7D). Table 1 summarises our ﬁndings allowing comparison of the
effects of STO-609 on thrombin-induced phosphorylation of AMPK
and eNOS as well as the effect of A23187 on ATP levels in different
media.
4. Discussion
Data presented in this paper show that in cultured endothelial
cells, two upstream pathways are involved in mediating the effects of
thrombin stimulation on AMPK phosphorylation and activation, one
pathway involving stimulation of CaMKK and another dependent on a
rise in AMP/ATP ratio presumably involving LKB1. Furthermore, we
demonstrate that environmental/culture conditions dictate which
signal transduction pathways are activated by thrombin stimulation.
Under culture conditions that do not allow or facilitate a fall in ATP
after stimulation with thrombin AMPK activation is exclusively
mediated by CaMKK and does not contribute to the phosphorylation
of eNOS. In contrast, conditions subjecting endothelial cells to a fall in
ATP when stimulated with thrombin facilitate activation of AMPK-
dependent signal transduction pathways which stimulate down-
stream phosphorylation of eNOS.
Thus, our results suggest that only AMPK activated in response to a
fall in ATP is involved in the phosphorylation of eNOS. A possible
explanation may be provided by the allosteric effects that AMP has on
AMPK [19–21], independent of the upstream AMPK kinase. Sanders et
al. [19] have proposed a revised model for activation of AMPK that
accounts for activation of AMPK by two distinct signals: a Ca+2-
dependent pathway, mediated by CaMKKβ and an AMP-dependent
pathway, mediated by LKB1. In circumstances, where AMP and Ca+2
rise in concert, both pathways could operate. In such conditions both
CaMKKβ and LKB1 would contribute to AMPK activation as we have
demonstrated in medium 199 and in 1640 when the cells were pre-
treated with 2-deoxy-glucose. Thus, the activation of AMPK based on
elevation of AMP may be critical for AMPK-dependent eNOSphosphorylation mediated by thrombin in endothelial cells but this
proposed mechanism needs further study.
In view ofmarked differences between the composition of medium
199 and medium 1640 we examined several possibilities that could
explain the different responses to stimulation in the different media.
These included the presence of purines (ATP, UTP, adenosine, xanthine
and hypoxanthine), cholesterol and vitamins, including tocopheryl
phosphate, in medium 199. However, after these were excluded we
found a clear difference in ATP levels within cells after stimulation
depending on the presence of the non-ionic detergent tween 80 in the
medium. Adding tween 80 (0.2 mg/L) to medium 1640 resulted in a
15% fall in cellular ATP after ionophore treatment. Also, the addition of
tween 80 to medium 1640 resulted in a similar activation of
downstream pathways after thrombin treatment (AMPK, ACC and
eNOS phosphorylation) as in cells stimulated in medium 199.
However, tween 80 is not responsible for the entire ATP lowering
observed after ionophore treatment in medium 199. The non-
involvement of nucleotides was particularly unexpected as the ATP
lowering was prevented by apyrase or phosphatase pre-treatment.
Tween 80 is added to culture media in miniscule amounts to
facilitate solubilisation of cholesterol. Its addition obviously repre-
sents an artiﬁcial condition without a deﬁnite physiological or
pathophysiological signiﬁcance. However, in this study the experi-
mental conditions including tween 80 allowed energy deprivation
within endothelial cells after thrombin stimulation thus uncovering
the two pathways for AMPK activation, one of which mediates the
downstream activation of eNOS. Also, the conditions for the activation
of these pathways, i.e. energy deprivation or Ca+2-release, were
identiﬁed. Finally, energy deprivation is of obvious interest and
potential importance in pathophysiology.
Effects of histamine and thrombin on intracellular energy status
have previously been reported. It has been shown that thrombin
increases the extracellular acidiﬁcation rate of endothelial cells,
suggesting its stimulation of rapid metabolic responses [22]. Similar
results have been demonstrated after treatment with histamine [23].
These reports are consistent with our ﬁndings that thrombin lowers
cellular ATP levels in endothelial cells which we suggest plays a role in
an AMPK-dependent pathway mediating stimulatory signals from G-
protein coupled receptors to eNOS phosphorylation in medium 199.
While the basis for the different downstream effects of AMPK
depending on its mode of activation is unclear, a possible explanation
might involve isoform speciﬁc phosphorylation of eNOS. In skeletal
muscle, heart and liver, the two isoforms of AMPK are differently
activated [24–30]. The α2 isoform has in several reports been shown
to be activated by LKB1 [24,26] or the adenosine analogue 5-
aminoimidazole-4-carboxamide-1-β-4 ribofuranoside (AICAR)
[27,28], while the α1 isoform is stimulated by CaMKK [29]
independently of AMP concentration [26]. It has also been observed
in vitro that complexes containing the α2 rather than the α1 isoform
have a greater dependence on AMP both in direct allosteric activation
and in reactivation by an upstream kinase [30]. Tzatsos and Tsichlis
recently demonstrated, using several agonists, that in HEK293 cells,
activation of the α1 subunit was mediated by CaMKKβ whereas the
activation of α2 was mediated by LKB1 [31]. Finally, two reports have
just been published, demonstrating isoform speciﬁc phosphorylation
of AMPK targets. McGee et al. demonstrated in skeletal muscle that
theα1 isoform, independently of LKB1, mediated the phosphorylation
of the mammalian target of rapamycin complex 1 (mTORC1) leading
to inhibition of muscle growth [32]. Qin and De Vries demonstrated
that although phosphorylation of the α1 isoform is dominant in RPE
cells after H2O2 treatment, the phosphorylation of the AMPK
substrate ACC as well as the effects on phagocytosis are mediated
by the α2 subunit [33].
Endothelial cells also dominantly express the α1 isoform of AMPK
[34] and it has even been doubted whether they express the α2
isoform at all [35]. While in the present study probing with
Fig. 7. The effects of tween 80 on the phosphorylation of eNOS and AMPK in different media. (A) The effects of 20min pre-treatment with STO-609 (10 μM) on AMPK phosphorylation
(Thr172) after thrombin (1 U/mL, 2 min) in 1640 with tween 80 (20mg/L). (B) The effects of 20 min pre-treatment with STO-609 or compound C (10 μM) on thrombinmediated eNOS
phosphorylation (Ser1177) inmedium 1640with tween 80. (C) eNOS phosphorylation after thrombin treatment and the effects of 20min pre-treatment with STO-609 or compound C
inWilliamsmediumwith or without tween 80. (D) AMPK phosphorylation after thrombin and the effects of 20min pre-treatment with STO-609 inWilliamsmediumwith orwithout
tween 80. Cells were treated and results expressed as described in Fig. 2 and show the average±S.D. of three independent experiments. (†ns/⁎pb0.05 cells treated with inhibitor and
thrombin vs. cells treated with thrombin alone; ††ns/#pb0.05 vs. unstimulated cells).
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α1 subunit the expression of both isoforms was clearly demonstrated
by the use of isoform speciﬁc antibodies. Furthermore, each isoform
could be downregulated separately by isoform speciﬁc siRNA.
Although such separate interference with either isoform did not
affect eNOS phosphorylation simultaneous treatment with both α1
and α2 siRNA caused 42% inhibition of eNOS phosphorylation and a
signiﬁcant reduction in cGMP-production in cells maintained in
culture medium 199. This treatment had no effect on eNOS
phosphorylation or activity in medium 1640. These results strengthen
the conclusions from the work with the AMPK inhibitor Compound Cbut do not support isoform speciﬁc phosphorylation of eNOS. Other
isoform speciﬁc effects are, however, not excluded and we observed
that treatment with α2 siRNA for more than 48 h caused morpho-
logical changes of the cells not caused by α1 siRNA (not shown).
Stahmann et al. [14] used thrombin as an agonist and showed total
inhibition of AMPK phosphorylation by STO-609 in HUVEC. They
demonstrated that eNOS phosphorylation by thrombin was not
caused by AMPK since inhibition of CaMKK or AMPK or their
downregulation by siRNA had no effects on eNOS phosphorylation
or NO-synthesis. Neither did they see any changes in intracellular ATP
levels after treatment with thrombin. These results are similar to our
Table 1
Comparison of the effect of STO-609 on AMPK and eNOS phosphorylation after
thrombin treatment in different media and comparison of the effect of A23187 on
cellular ATP levels in different media
% inhibition of AMPK
phosphorylation
% inhibition of eNOS
phosphorylation
% ATP lowering
Medium STO-609 STO-609
199 72±11 54±14 53±3
199+ phosphatase 100±15 0 9±1
1640 95±6 1±14 2±4
1640+ tween 69±21 35±6 15±6
Williams 99±8 0±16 17±9
Williams+
tween
76±9 41±11 50±12
Data were expressed as percent inhibition of phosphorylation relative to thrombin-
stimulated cells without inhibitors and percent lowering of ATP after A23187 treatment
relative to unstimulated cells. Data taken from experiments presented in Figs. 1–7.
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Williams or in medium 199 after treatment with apyrase or acid
phosphatase. However, inmedium 199 or after addition of tween 80 to
Williams or 1640, STO-609 only caused partial inhibition of AMPK
phosphorylation revealing involvement of a different AMPK kinase,
presumably LKB1. Under these circumstances, STO-609 partially
inhibited eNOS phosphorylation. Furthermore, as summarized in
Table 1, these are the conditions where activation caused a decrease in
ATP levels allowing allosteric activation of AMPK as well as
phosphorylation by LKB1.
This study did not address the mechanisms by which tween 80 or
other constituents of culture medium 199 facilitate the lowering of
ATP after thrombin stimulation. Several potentially important
upstream events were not studied either such as changes in G-protein
coupling and/or interaction with the receptor nor changes in the
localization of LKB1 or eNOS.
In conclusion, we show that culture conditions affect endothelial
signal transduction pathways. Conditions that subject endothelial
cells to a fall in ATP after thrombin stimulation facilitate activation of
pathways that are partly dependent on AMPK, cause downstream
phosphorylation of eNOS and enhance the magnitude of the response.
In contrast, under culture conditions that do not facilitate a fall in ATP
after stimulation AMPK activation is exclusively mediated by CaMKK
and does not contribute to the phosphorylation of eNOS. In addition to
furthering our knowledge on the mechanisms of thrombin mediated
stimulation of eNOS, this work has demonstrated how environmental
conditions can dictate which signal transduction pathways are
activated in endothelial cells and speciﬁcally highlighted the impor-
tance of cellular energy levels in endothelial signalling.
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